
Rett Syndrome Drug Race Intensifies as Gene Therapies Challenge Trofinetide’s Market Reign | Competitive Intelligence
Rett syndrome care is evolving as DAYBUE leads the market and next-gen therapies like gene and neuroplasticity agents aim to redefine treatment standards AUSTIN, TX, UNITED STATES, June 2, 2025 /EINPresswire.com/ -- Rett Syndrome Drug Race …